MCC950 . sodium salt [256373-96-3]

Catalog number: AG-CR1-3615-M001
Brand: AdipoGen Life Sciences
Packing: 1 mg
Other sizes: 5 mg
10 mg
Price: € 45.00
Expected delivery time: 7 days
Quantity:
Chemical Structure

Product specifications for - MCC950 . sodium salt [256373-96-3]

Overview: 
Product group: Chemicals
Category: Other
CAS No.: 256373-96-3
Properties: 
Purity: >98% (HPLC)
Molecular Formula: C20H23N2NaO5S
Molecular weight: 426.5
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Storage instructions: Store at -20°C
Scientific information: 
Scientific info: Potent, selective and orally available NLRP3 inflammasome inhibitor. Blocks the release of IL-1beta in macrophages primed with LPS and activated with ATP or nigericin, but it does not inhibit NLRP1, NLRC4, AIM2, TLR2 signaling or priming of NLRP3. Prevents oligomerization of ASC in cells stimulated with LPS and nigericin. Active in vivo, blocking the production of IL-1beta and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome (CAPS). Also active in ex vivo samples from individuals with Muckle-Wells syndrome. Potential therapeutic agent for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases.
Safety information: 
MSDS: MSDS
Hazard information: H302, H315, H319, H335
Additional information: 
Synonyms: AG-CR1-3615-M001; AdipoGen Life Sciences
Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing: R.E. Laliberte, et al.; J. Biol. Chem. 278, 16567 (2003) Read more
Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methylethyl)furan-2-sulfonyl]urea, an antiinflammatory agent: F.J. Urban, et al.; Synth. Commun. 33, 2029 (2003) Read more
The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes: R.C. Coll, et al.; PLoS One 6, e29539 (2011) Read more
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases: R.C. Coll, et al.; Nat. Med. 21, 248 (2015) Read more
Taming the inflammasome: M. Levy, et al.; Nat. Med. 21, 213 (2015) Read more
The Nlrp3 inflammasome admits defeat: C.J. Gross & O. Gross; Trends Immunol. 36, 323 (2015) Read more